Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition ClosesThe Motley Fool • 04/16/19
Bristol-Myers CEO: We're 'one step closer to creating that great company' with CelgeneCNBC • 04/12/19
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New DealZacks Investment Research • 04/12/19
3 Reasons Bristol-Myers Could Become One Of The Best Investments Of The Next 5 YearsSeeking Alpha • 04/08/19
Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY)Zacks Investment Research • 04/08/19
Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMSSeeking Alpha • 03/31/19
Celgene shares pop after top proxy advisor ISS recommends Bristol-Myers investors approve buyout bidCNBC • 03/29/19
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug ApprovalsZacks Investment Research • 03/29/19
Key Celgene Issue That Could 'Unnerve' Bristol Takeover Was Just TossedInvestors Business Daily • 03/14/19